BACK
TO MAIN
PAGE

Epstein-Barr virus (EBV) infection

General Information

Epstein-Barr virus (EBV) is a member of the herpes virus family.

EBV is the first human tumour virus discovered and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers, such as Burkitt lymphoma (BL), Hodgkin lymphoma (HL), post-transplant lymphoproliferative disorder (PTLD), nasopharyngeal carcinoma (NPC), and gastric carcinoma (GC). 

EBV is also the primary cause of infectious mononucleosis that could cause persistent fatigue for up to 6 months and cause severe neurologic, haematologic, or liver complications.

EBV has been shown to play a critical role in the pathogenesis of multiple sclerosis. 

There are no vaccines or treatments against EBV infection.

Show More

Epidemiology

Up to 70% of adolescents and young adults in developed countries suffer from infectious mononucleosis.​

Each year EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths worldwide. 

Vaccines
Pipeline

2
Vaccines in
the pipeline

Technology Platforms

  • mRNA (2)

DEVELOPMENT PHASES

  • Phase I (2)

TRIAL POPULATION

  • Adults (2)

Sources: 
https://www.cdc.gov/epstein-barr/about-ebv.html
https://doi.org/10.3389/fimmu.2021.734471​​
[Accessed: November 2022]

Vaccines Europe Pipeline Review

Download our pipeline review